Revolutionizing cardiovascular medicine: targeted therapies for the cardiac conduction system

J Clin Invest. 2022 Oct 17;132(20):e164192. doi: 10.1172/JCI164192.


Arrhythmogenic cardiovascular disorders are associated with considerable morbidity and mortality. Whether cardiac conduction disease is caused by genetic defects, procedural perturbations, valvular disease, ischemia, aging, or heart failure, new therapies are warranted. In this issue of the JCI, Goodyer et al. used state-of-the-art technologies to image the cardiac conduction system (CCS) in real time and to deliver targeted therapies to the CCS and its subcomponents. These findings advance the ability to image and treat specific lineages within the adult heart with the potential for broader applications in the treatment of cardiovascular diseases.

Publication types

  • Comment

MeSH terms

  • Adult
  • Arrhythmias, Cardiac* / drug therapy
  • Arrhythmias, Cardiac* / genetics
  • Heart
  • Heart Conduction System*
  • Humans